Method for detecting enantiomers in viloxacin medicine
Through the combination of high performance liquid chromatography with specific mobile phase and chromatographic column fillers, the problem of R-configuration and S-configuration enantiomer detection in veroxaqin drugs was solved, achieving efficient and accurate separation and Testing ensures consistency in drug quality.
Patent Information
- Application Number
- CN202410693244.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2024-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
The existing detection methods cannot effectively isolate and detect the R-configuration and S-configuration enantiomers in veroxaqin drugs, resulting in inconsistent quality of active ingredients in generic drugs and affecting the bioavailability of the drug.
High performance liquid chromatography was used to use amylose-tris(3-chloro-5-methylphenylcarbamate) covalently bonded silica gel as chromatographic column filler, combining ammonium bicarbonate aqueous solution, acetonitrile and methanol , ethanol or its mixture as mobile phase, and isometric or linear gradient elution, the separation and detection of the R-configuration and S-configuration enantiomers in veroxaxin drugs are achieved.
Accurate detection of R-configuration and S-configuration enantiomers in Veroxaqin drugs, with high resolution, ease of operation and durability, meeting the detection requirements of enantiomer content in generic drugs , ensure the consistency of product quality.
Smart Images

Figure CN119064489A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of drug analysis, and particularly relates to a method for detecting enantiomers in a viloxazine drug. Background Art
[0002] Viloxazine is a morpholine derivative and a selective norepinephrine reuptake inhibitor. It was developed by Supernus Pharma and approved by the U.S. Food and Drug Administration (FDA) in April 2022 for the treatment of attention deficit hyperactivity disorder (ADHD) in adolescents and adults aged 6 years and above. The trade name is Qelbree, and the active ingredient is viloxazine hydrochloride. The drug preparation is a sustained-release capsule. Qelbree is the first new non-stimulant drug for the treatment of ADHD in children and adolescents in more than 10 years.
[0003] Viloxazine hydrochloride, chemical name: (±)-2-[(2-ethoxyphenoxy)methyl]morpholine hydrochloride, is a racemic compound with two stereoisomers (R-viloxazine hydrochloride and S-viloxazine hydrochloride), the structure of which is as follows:
[0004] The carbon atom marked with "*" is a chiral carbon.
[0005] The two enantiomers in the structure of Viloxacin are R-configuration and S-configuration. The structure of Viloxacin is as follows:
[0006]
[0007] In February 2016, the General Office of the State Council issued the "Opinions on Conducting the Evaluation of the Quality and Efficacy Consistency of Generic Drugs" (Guobanfa
[2016] No. 8), which put forward specific opinions on the consistency evaluation work. The connotation of the consistency evaluation of generic drug quality is drug therapeutic equivalence, including pharmaceutical equivalence and bioequivalence. Pharmaceutical equivalence refers to the similarity of the pharmaceutical properties of generic drugs and reference preparations, including raw materials and excipients, dosage forms, prescriptions, processes, in vitro experiments and other studies. Bioequivalence refers to the fact that there is no statistical difference in the degree and speed of drug absorption between generic drugs and reference preparations under the same conditions.
[0008] The quality of the active pharmaceutical ingredient (API) in the formulation is the source. If the active pharmaceutical ingredient used in the generic drug is significantly different from the reference drug, it will lead to differences in efficacy and ultimately lead to differences in the bioavailability of the drug in the human body. The active ingredient of Qelbree is a racemate of R-configuration and S-configuration. Therefore, in the development of generic viloxazine hydrochloride drugs, it is necessary to ensure that the content of R-configuration and S-configuration enantiomers in the active ingredient used in the generic drug is basically consistent with that of the original Qelbree.
[0009] Reference 1 (Biomed. Chromatogr. 2014; 28: 120–126) discloses a method for characterizing the interaction between active enantiomers of drugs and highly sulfated β-cyclodextrin using countercurrent capillary electrophoresis. An appropriate amount of NaH2PO4-2H2O was dissolved in water, and the pH was adjusted with 1 μm NaOH to obtain a BGE containing 30 mM phosphate at pH 7.0; a 200 μM racemic drug solution was prepared in the BGE and injected into the electrophoresis system. The complete filling technique (CFT) in countercurrent mode was used to separate the enantiomers of 8 psychoactive drugs for the first time, including viloxazine, where the resolution (Rs) of viloxazine enantiomers was 0.9 to 3.0. Compared with high performance liquid chromatography, countercurrent capillary electrophoresis has poor reproducibility in migration time, is complex to operate, and has low separation.
[0010] Document 2 (Journal of Chromatography A. Volume 1567, 14 September 2018, Pages 111-118) discloses a study on the enantiomeric separation ability of neutral and basic chiral compounds under reverse phase conditions using cellulose tris (3,5-dichlorophenylcarbamate) stationary phase, using an immobilized cellulose tris (3,5-dichlorophenylcarbamate) column (Chiralart Cellulose-SC; 3μm, 150×4.6mm id; YMC Separation Technology Co., Ltd.; Tokyo, Japan), with a ternary mixture of ammonium acetate buffer (10mM, pH 8) / acetonitrile / diethylamine (60 / 40 / 0.1, v / v / v) as the mobile phase, a mobile phase flow rate of 1.0mL / min-1, and an injection volume of 2uL. The detection wavelength is 220nm, and the column is kept at a constant temperature of 25°C. Table 1 shows that the resolution Rs of the method for the enantiomers of viloxazine is 0, that is, the two enantiomers of viloxazine cannot be separated.
[0011] At present, there is no literature report that HPLC can effectively separate and detect R-configuration and S-configuration enantiomers in viloxazine or its pharmaceutical preparations. Therefore, it is urgent to develop a method that is simple to operate and can accurately and effectively detect R-configuration and S-configuration enantiomers in viloxazine or its pharmaceutical preparations to meet the needs of viloxazine generic drug development. Summary of the invention
[0012] The present invention aims to provide a method for detecting R-configuration and S-configuration enantiomers in a viloxazine drug by high performance liquid chromatography, which has the advantages of simple operation, good separation, strong specificity, good durability, etc. The method can meet the detection requirements of the enantiomer content in the viloxazine hydrochloride raw material or its preparation, and effectively control the product quality.
[0013] Specifically, the present invention provides a method for detecting R-configuration and S-configuration enantiomers in a viloxazine drug, the method comprising:
[0014] The method adopts a high performance liquid chromatography method, uses a silica gel covalently bonded with amylose-tris(3-chloro-5-methylphenylcarbamate) on the surface as a chromatographic column filler, and adopts an ultraviolet detector; the mobile phase A is an aqueous solution of ammonium bicarbonate, and the mobile phase B is acetonitrile, methanol, ethanol, isopropanol or a mixture thereof; and uses a mixture of the mobile phases A and B for elution to separate and detect R-configuration and S-configuration enantiomers in the viloxazine drug;
[0015] The structures of the R-configuration and S-configuration enantiomers in the viloxazine drug are as follows:
[0016]
[0017] In one embodiment, in the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug, the mobile phase A is a 15-30 mM ammonium bicarbonate aqueous solution, preferably a 20 mM ammonium bicarbonate aqueous solution.
[0018] In one embodiment, in the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug, the mobile phase B is acetonitrile.
[0019] In one embodiment, the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug, wherein the elution mode can be isocratic elution or linear gradient elution; wherein the isocratic elution preferably has a volume ratio of mobile phase A to mobile phase B of (50-70):(30-50), for example 50:50, 55:45, 60:40, 65:35, 70:30 and any value therebetween, preferably 65:35.
[0020] In another embodiment, the elution method may also be linear gradient elution, for example, the gradient elution conditions are:
[0021]
[0022] In the embodiments of the present invention, isocratic elution has the advantages of better separation and more convenient operation, so it is more preferred that the elution mode is isocratic elution.
[0023] In one embodiment, the detection method of R-configuration and S-configuration enantiomers in the viloxazine drug of the present invention, wherein the chromatographic column uses a chromatographic column with a silica gel surface covalently bonded with amylose-tris (3-chloro-5-methylphenylcarbamate) as a filler, and the chromatographic column specifications are: column length between 150mm and 300mm, chromatographic column inner diameter between 1mm and 10mm, particle size between 3μm and 5μm, and the chromatographic column specifications are preferably 4.6mm*150mm, 5μm. CHIRALPAK IG series chromatographic columns are preferred, and CHIRALPAK IG is particularly preferred, with a specification of 4.6×250mm and a filler particle size of 5μm.
[0024] In one embodiment, the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug, wherein the chromatographic conditions of the high performance liquid chromatography further include:
[0025] The flow rate is 0.5-1.0 ml / min, preferably 0.5-0.7 ml / min, for example 0.5 ml / min, 0.6 ml / min, 0.7 ml / min and any value therebetween; preferably 0.6 ml / min; in the technical scheme described in the present invention, when other chromatographic conditions remain unchanged, the adjustment of the flow rate will affect the elution time of the R-configuration and S-configuration enantiomers, for example, when the flow rate is 1.0 ml / min and the relative flow rate is 0.6 ml / min, the elution time of the R-configuration and S-configuration enantiomers will be simultaneously advanced, but still meet the separation and detection requirements;
[0026] Further preferably, the column temperature is 20 to 40°C, such as 23°C, 24°C, 25°C, 26°C, 27°C, 30°C, 35°C, 40°C and any value therebetween; preferably 25°C to 40°C;
[0027] Further preferably, the detection wavelength is 190nm to 230nm, preferably 196nm to 230nm, for example 190nm, 196nm, 198nm, 199nm, 200nm, 201nm, 202nm, 203nm, 204nm, 210nm, 220nm, 230nm and any value therebetween, more preferably 200nm;
[0028] More preferably, the injection volume is 1 μl to 10 μl, for example, 1 μl, 2 μl, 3 μl, 4 μl, 5 μl, 6 μl, 7 μl, 8 μl, 9 μl, 10 μl and any value therebetween, preferably 3 to 5 μl.
[0029] In an embodiment of the present invention, the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug also includes the preparation of a test solution, comprising the following steps:
[0030] Take the Viloxacin API or its pharmaceutical preparation, accurately weigh it, and prepare it with a diluent;
[0031] Optionally, the method further comprises the preparation of a reference solution, comprising the following steps: the reference solution is R-configuration and S-configuration enantiomers of viloxazine, the reference solution is accurately weighed, and the solution is prepared with a diluent respectively;
[0032] The diluent is a mixed solution of one or more of the mobile phase, acetonitrile, methanol, and water. In one embodiment, for example, the diluent is a mobile phase, i.e., a mixed solution of mobile phases A and B; in one embodiment, the diluent is acetonitrile, methanol or water; in one embodiment, the diluent is a mixed solution of acetonitrile and water; in one embodiment, the diluent is a mixed solution of methanol and water; in one embodiment, the diluent can also be a mixed solution of methanol, acetonitrile and water; in another embodiment, the diluent is a mixed solution of any one of methanol, acetonitrile or water and the mobile phase. When the diluent is a mixed solution of two or more of methanol, acetonitrile, water, and mobile phase, the content of each component in the mixed solution can be arbitrary; for example, when the diluent is a mixed solution of acetonitrile and water, the volume ratio of acetonitrile to water can be any value, such as any value between 0.001:99.999 and 99.999:0.001, such as (0.1-10):1, (0.5-5):1, (1-20):1 or 1:1, etc. For example, when the diluent is a mixed solution of methanol and water, the volume ratio of methanol to water can be any value, such as any value between 0.001:99.999 and 99.999:0.001, such as (0.1-10):1, (0.5-5):1, (1-20):1 or 1:1, etc. During the research process, it was found that since viloxazine pharmaceutical preparations, especially viloxazine sustained-release capsules, contain more excipients, mixed solutions of methanol and water, and mixed solutions of acetonitrile and water have better solubility or dispersibility for them, and also have better solubility for viloxazine raw materials. Therefore, when preparing the test solution, a mixed solution of methanol and water, or a mixed solution of acetonitrile and water is more preferred; for example, a solution with a volume ratio of methanol to water of (0.1 to 10):1, preferably 1:1, and a solution with a volume ratio of acetonitrile to water of (0.1 to 10):1, preferably 1:1.
[0033] Further preferably, the concentration of the test solution is 0.3 mg / ml-2 mg / ml, more preferably 0.4 mg / ml;
[0034] Further preferably, the concentrations of the R-configuration and S-configuration enantiomer reference solutions of viloxazine are 0.3 mg / ml-2 mg / ml, more preferably 0.4 mg / ml.
[0035] In a more specific embodiment, the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug of the present invention further comprises the preparation of a test solution, and optionally, further comprises the preparation of a reference solution (R-configuration and S-configuration enantiomers, respectively);
[0036] Furthermore, the preparation of the test solution includes: taking about 23 mg of viloxazine hydrochloride, accurately weighing, placing in a 50 ml volumetric flask, ultrasonically dissolving and diluting to the scale with a diluent, shaking well, and preparing a solution containing about 0.4 mg of viloxazine per 1 ml.
[0037] Further, the preparation of the reference substance (R-configuration and S-configuration enantiomers, respectively) solution comprises:
[0038] Preparation of R-enantiomer solution of viloxazine: Take about 23 mg of R-enantiomer of viloxazine hydrochloride, accurately weigh it, put it in a 50 ml volumetric flask, dissolve it with ultrasonic diluent and dilute it to the scale, shake it well, and prepare a solution containing about 0.4 mg of R-enantiomer of viloxazine per 1 ml.
[0039] Preparation of S-enantiomer solution of viloxazine: Take about 23 mg of S-enantiomer of viloxazine hydrochloride, accurately weigh it, put it in a 50 ml volumetric flask, dissolve it with ultrasonic diluent and dilute it to the scale, shake it well, and prepare a solution containing about 0.4 mg of S-enantiomer of viloxazine per 1 ml.
[0040] In one embodiment, the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug of the present invention further comprises: accurately measuring the test solution and injecting it into the chromatograph, and recording the chromatogram.
[0041] The detection method of the present invention can calculate the peak area volume ratio, or use the external standard method to calculate the content of R-configuration of viloxazine and S-configuration of viloxazine or the ratio of the two by peak area; for example, for both viloxazine raw materials and preparations, the ratio of the two enantiomers can be calculated by the peak area volume ratio, or the content of R-configuration of viloxazine and S-configuration of viloxazine can be calculated by the external standard method according to the peak area.
[0042] In one embodiment, the method for detecting R-configuration and S-configuration enantiomers in the viloxazine drug of the present invention, wherein the viloxazine drug includes a viloxazine bulk drug or a viloxazine pharmaceutical preparation; preferably, the viloxazine bulk drug can be either a viloxazine free base or a pharmaceutically acceptable salt of viloxazine, such as viloxazine hydrochloride; the viloxazine pharmaceutical preparation is preferably a viloxazine sustained-release capsule, in particular a viloxazine sustained-release capsule with the same or similar ingredients as Qelbree.
[0043] The beneficial effects of the present invention are:
[0044] The present invention provides for the first time a method for effectively separating and detecting R- and S-enantiomers in a viloxazine drug by high performance liquid chromatography. The method provided by the present invention has the advantages of good system applicability and good separation of R- and S-enantiomers of viloxazine for detecting R- and S-enantiomers in viloxazine drugs; and the method of the present invention has high accuracy and can meet the content detection of two enantiomers in viloxazine drugs. Other features and advantages of the present invention are further described and illustrated by subsequent examples and drawings.
[0045] Definition of terms
[0046] The present invention is intended to cover all substitutions, modifications and equivalent technical solutions, which are all included in the scope of the present invention as defined in the claims. Those skilled in the art will recognize that many methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is in no way limited to the methods and materials described herein. In the event that one or more of the combined documents, patents and similar materials are different from or contradictory to the present application (including but not limited to defined terms, term applications, described technologies, etc.), the present application shall prevail.
[0047] It should be further appreciated that certain features of the invention, which for clarity are described in multiple separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which for brevity are described in a single embodiment, may also be provided separately or in any suitable sub-combination.
[0048] Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. All patents and publications related to the present invention are incorporated herein by reference in their entirety.
[0049] The term “comprise” or “include” is an open expression, that is, including the contents specified in the present invention but not excluding other contents.
[0050] In the context of the present invention, all the numbers disclosed herein are approximate values, regardless of whether the words "about" or "approximately" are used. The value of each number may vary by less than 10% or a reasonable difference considered by those skilled in the art, such as 1%, 2%, 3%, 4% or 5%.
[0051] The "viloxazine pharmaceutical preparation" in the context of the present invention refers to a drug obtained by combining the viloxazine API with a pharmaceutically acceptable pharmaceutical excipient or excipient in different administration forms in accordance with the Drug Administration Law of the People's Republic of China and / or the Pharmacopoeia, such as viloxazine sustained-release capsules. The viloxazine sustained-release capsules described in the present invention refer to Qelbree or a viloxazine pharmaceutical preparation that is the same or similar to Qelbree in terms of composition.
[0052] The "raw drug" described in the context of the present invention is consistent with the definition of raw drugs by the World Health Organization, wherein the "viloxazine raw drug" specifically includes viloxazine or a pharmaceutically acceptable salt thereof. Preferably, in the present invention, the "viloxazine raw drug" is viloxazine free base or viloxazine hydrochloride.
[0053] The abbreviation mM means millimole per liter (0.001 mol / L), for example, "20 mM ammonium bicarbonate in water" means 0.02 mol / L ammonium bicarbonate in water. BRIEF DESCRIPTION OF THE DRAWINGS
[0054] Figure 1 : HPLC chart showing the S-configuration solution of viloxazine detected by the method of Example 1; wherein the peak time of the S-configuration of viloxazine is RT=20.052min;
[0055] Figure 2 : HPLC chart showing the R-configuration solution of viloxazine detected by the method of Example 1; wherein the peak time of the R-configuration of viloxazine is RT=14.020min;
[0056] Figure 3 : HPLC graph showing the test solution of viloxazine (racemate) detected by the method of Example 1; wherein the separation degree between the viloxazine S-configuration and the viloxazine R-configuration is 7.15;
[0057] Figure 4 : HPLC graph showing the diluent detected by the method of Example 1;
[0058] Figure 5 : HPLC chart showing the test sample viloxazine pharmaceutical preparation in Example 2;
[0059] Figure 6 : A partial diagram showing the HPLC of the Viloxaquin API detected by the method of Example 3;
[0060] Figure 7 : HPLC chart showing the detection of the Viloxacin API by the method of Comparative Example 1;
[0061] Figure 8 : HPLC chart showing the detection of the Viloxacin API by the method of Comparative Example 2;
[0062] Fig. 9 : HPLC chart showing the detection of Viloxacin API by the method of Comparative Example 3;
[0063] Fig.10 : HPLC chart showing the detection of the Viloxaquin API by the method of Comparative Example 4. DETAILED DESCRIPTION
[0064] The technical scheme and beneficial effects of the present invention are further explained below in conjunction with specific embodiments. Unless otherwise specified, all scientific and technological terms used in the present invention have the same meaning as those generally understood by technicians in the field to which the present invention belongs. The experimental methods for which specific conditions are not specified in the following examples are usually carried out under conventional conditions or under conditions recommended by the manufacturer. Unless otherwise specified, the raw materials and reagents used in the following examples are all commercially available products. The mobile phase solvents used are all chromatographically pure reagents; the detection instrument used is Shimadzu high performance liquid chromatograph (LC-2030C PLUS (CN); the viloxazine pharmaceutical preparation used is viloxazine sustained-release capsules (trade name: Qelbree, purchased from Supernus Pharmaceuticals); the viloxazine raw material used is viloxazine hydrochloride (purity not less than 98%) produced by Suzhou Enhua Biopharmaceutical Technology Co., Ltd.
[0065] The present invention provides a method for detecting enantiomers in a viloxazine drug, the method comprising:
[0066] (a) preparing a test solution and optionally a reference solution;
[0067] (b) using silica gel having amylose-tris(3-chloro-5-methylphenylcarbamate) covalently bonded on the surface as a chromatographic column filler;
[0068] (c) mobile phase A is an aqueous solution of ammonium bicarbonate, and mobile phase B is acetonitrile;
[0069] (d) detecting with an ultraviolet detector;
[0070] Wherein, the test sample is a viloxazine drug, preferably a viloxazine API (such as viloxazine hydrochloride or viloxazine free base) or a viloxazine sustained-release capsule;
[0071] The diluent is a mobile phase, acetonitrile, methanol, water or one or more mixed solutions thereof, preferably the diluent is a mixture of methanol and water, or a mixture of acetonitrile and water, more preferably the volume ratio of methanol to water is 1:1, and the volume ratio of acetonitrile to water is 1:1.
[0072] Preferably, the test solution in step (a) is prepared with a diluent having a concentration of 0.3 mg / ml-2 mg / ml, preferably 0.4 mg / ml;
[0073] Optionally, the reference substance solution is prepared with a diluent at a concentration of 0.3 mg / ml-2 mg / ml, preferably 0.4 mg / ml; the reference substances are R-configuration and S-configuration enantiomers of viloxazine respectively;
[0074] Preferably, step (b) uses a high performance liquid chromatography column CHIRALPAK IG, 4.6×250 mm, and a filler particle size of 5 μm;
[0075] Preferably, in step (c), mobile phase A is an aqueous solution of 15-30 mM ammonium bicarbonate, preferably an aqueous solution of 20 mM ammonium bicarbonate; isocratic elution is adopted, wherein the volume ratio of mobile phase A to mobile phase B is (50-70):(30-50), preferably 65:35.
[0076] Preferably, the chromatographic conditions of the high performance liquid chromatography also include:
[0077] The flow rate is 0.5-1.0 ml / min, preferably 0.6 ml / min;
[0078] The column temperature is 20-40°C, preferably 25-30°C;
[0079] The injection volume is 1 μl to 10 μl, preferably 5 μl.
[0080] Preferably, step (d) is detected using an ultraviolet detector, and the detection wavelength is set to 190nm to 230nm, preferably 200nm;
[0081] Preferably, accurately measure equal volumes of the test solution and the reference solution, respectively, and inject them into a liquid chromatograph, record the chromatogram, and calculate the content or relative ratio of the R-configuration and S-configuration enantiomers of viloxazine by the peak area-volume ratio or by the external standard method according to the peak area;
[0082] Preferably, the relative ratio of the R-configuration and S-configuration enantiomers in the viloxazine raw material and preparation is calculated by peak area percentage, or the content of the R-configuration and S-configuration enantiomers in the viloxazine raw material and preparation is calculated by the external standard method according to the peak area.
[0083] Example 1: Detection of enantiomers in viloxazine API
[0084] Solution preparation:
[0085] (1) Preparation of diluent (methanol: water = 1:1):
[0086] Take 50ml of methanol and 50ml of water, mix and shake well.
[0087] (2) Sample solution preparation
[0088] ① Preparation of test solution: Take about 23 mg of viloxazine hydrochloride, accurately weigh it, put it in a 50 ml volumetric flask, dissolve it with a diluent by ultrasonic and dilute it to the scale, shake it well, and prepare a solution containing about 0.4 mg of viloxazine per 1 ml.
[0089] ② Preparation of R-viloxazine solution: Take about 23 mg of R-viloxazine hydrochloride, accurately weigh it, put it in a 50 ml volumetric flask, dissolve it with a diluent ultrasonically and dilute it to the scale, shake it well, and prepare a solution containing about 0.4 mg of R-viloxazine per 1 ml.
[0090] ③ Preparation of S-configuration of viloxazine solution: Take about 23 mg of S-configuration of viloxazine hydrochloride, accurately weigh it, put it in a 50 ml volumetric flask, dissolve it with ultrasonic diluent and dilute it to the scale, shake it well, and prepare a solution containing about 0.4 mg of S-configuration of viloxazine per 1 ml.
[0091] Detection:
[0092] Chromatographic conditions:
[0093] Detection wavelength: 200nm;
[0094] Column: CHIRALPAK IG, 4.6×250 mm, 5 μm;
[0095] Mobile phase A: 20 mM ammonium bicarbonate in water;
[0096] Mobile phase B: acetonitrile;
[0097] Isocratic elution: the volume ratio of mobile phase A to mobile phase B is 65:35;
[0098] Flow rate: 0.6ml / min
[0099] Column temperature: 25°C;
[0100] Injection volume: 5 μl;
[0101] Accurately measure 5 μl of the diluent solution, test solution, viloxazine R-configuration solution, and viloxazine S-configuration solution, respectively, and inject them into the liquid chromatograph to record the chromatogram.
[0102] Test results such as Figures 1 to 4 As shown, the HPLC diagram of the S-configuration solution of Viloxacin is as shown Figure 1 As shown, the peak time of the S-configuration of viloxazine is RT = 20.052 min;
[0103] The HPLC chart of R-form solution of Viloxacin is as follows: Figure 2 As shown, the peak time of R-configuration of viloxazine is RT = 14.020 min;
[0104] The HPLC chart of the test solution (viloxazine hydrochloride (racemic)) is as follows Figure 3 As shown;
[0105] The HPLC profile of the diluent is shown in Figure 4 shown.
[0106] from Figures 1 to 3 It can be seen that the S-configuration and R-configuration enantiomers in the viloxazine hydrochloride sample detected by the method of the present invention can be completely separated, with a separation degree of 7.15. Figure 4 It can be seen that the diluent does not interfere with the elution of the S-configuration and R-configuration of viloxazine.
[0107] Example 2: Detection method of R-configuration and S-configuration enantiomers in viloxazine pharmaceutical preparations:
[0108] Solution preparation:
[0109] (1) Preparation of diluent (methanol: water = 1:1)
[0110] Take 50ml of methanol and 50ml of water, mix and shake well.
[0111] (2) Preparation of test solution:
[0112] The test sample was viloxazine sustained-release capsules (trade name: Qelbree, specification 200 mg, purchased from Supernus Pharmaceuticals);
[0113] Preparation (Specification 200 mg) Test sample preparation: Take the contents of 1 capsule, place it in a 500 ml volumetric flask, ultrasonicate it with 250 ml of methanol, add water to stir, disperse, dilute to the scale, shake well, filter, and obtain a solution containing approximately 0.4 mg of viloxazine per 1 ml.
[0114] Detection:
[0115] The instrument and chromatographic conditions were the same as in Example 1;
[0116] Accurately measure 5 μl of the test solution and inject it into the liquid chromatograph to record the chromatogram.
[0117] Test results such as Figure 5 As shown, the peak time of the S-configuration enantiomer of viloxazine is RT = 19.983 min;
[0118] The elution time of the R-configuration enantiomer is RT = 13.935 min; the HPLC peak data are shown in Table 2.1 below:
[0119] Table 2.1 HPLC peak data of Viloxacin Capsules:
[0120]
[0121] from Figure 5 It can be seen from the peak data that the S-configuration of viloxazine and the R-configuration of viloxazine in the viloxazine sample detected by the method of the present invention are completely separated, and the separation degree is 7.02.
[0122] Example 3: Detection of enantiomers in viloxazine API
[0123] Solution preparation:
[0124] (1) Preparation of diluent (methanol: water = 1:1)
[0125] Take 50ml of methanol and 50ml of water, mix and shake well.
[0126] (2) Preparation of test solution
[0127] Test substance: Viloxacin hydrochloride;
[0128] Test solution: Take about 23 mg of viloxazine hydrochloride, weigh accurately, and place in a 50 ml volumetric flask. Then take appropriate amounts of 4 known impurities and add them to the volumetric flask. Use diluent to ultrasonically dissolve and dilute to the scale, shake well, and prepare a solution containing about 0.4 mg of viloxazine per 1 ml.
[0129] Detection:
[0130] Chromatographic conditions:
[0131] Detection wavelength: 200nm
[0132] Column: CHIRALPAK IG, 4.6×250 mm, 5 μm;
[0133] Mobile phase A: 20 mM ammonium bicarbonate in water;
[0134] Mobile phase B: acetonitrile;
[0135] Column temperature: 40°C;
[0136] Flow rate: 1.0ml / min;
[0137] Injection volume: 5 μl;
[0138] Perform linear gradient elution according to the following table:
[0139]
[0140] Accurately measure 5 μl of the test solution and inject it into the liquid chromatograph to record the chromatogram.
[0141] Test results such as Figure 6 As shown in the figure, the peaks at 15 to 22 minutes are the R-configuration and S-configuration enantiomers of viloxazine, which can achieve baseline separation. The peaks at 24 to 28 minutes are the four known impurities added.
[0142] The structures of the four known impurities are shown below:
[0143]
[0144] Comparative Examples 1 to 4: Detection Method of R-Configuration and S-Configuration Enantiomers in Viloxacin API
[0145] Preparation of test solution:
[0146] The test substance was viloxazine hydrochloride;
[0147] Test solution: Take about 23 mg of viloxazine hydrochloride, accurately weigh it, place it in a 50 ml volumetric flask, dissolve it with a diluent ultrasonically and dilute it to the scale, shake it well, and prepare a solution containing about 0.4 mg of viloxazine per 1 ml.
[0148] The liquid chromatography detection conditions are the same as those in Table D1.1. Take a certain amount of the test sample solution and inject it into the chromatograph. Elute according to the elution conditions and record the chromatogram.
[0149] Table D1.1 Chromatographic conditions:
[0150]
[0151] Table D1.2: Linear gradient elution
[0152]
[0153] Table D1.3: Linear gradient elution conditions
[0154]
[0155]
[0156] Test results:
[0157] The HPLC test was carried out according to the above conditions, and the results were as follows: Figures 7-10As shown in the figure, viloxazine has only one peak, and its R-configuration and S-configuration enantiomers cannot be separated. After adjusting the mobile phase, gradient, temperature and other related parameters, they still cannot be separated.
[0158] Example 4: Method Robustness:
[0159] The test solution was prepared in the same manner as in Example 1. The tolerance of the detection method was investigated when the chromatographic conditions were changed. The detection results under various chromatographic conditions are shown in Table 5.1 below.
[0160] Table 5.1 System durability test conditions and test results
[0161]
[0162] Conclusion: From the test results in Table 5.1, it can be seen that under various chromatographic conditions, the separation between the S-configuration and R-configuration enantiomers of viloxazine in each solution meets the requirements; and there is no obvious interference in the peak position, indicating that the method has good specificity.
[0163] From the above test results, it can be seen that the method provided by the present invention has the advantages of good separation, strong method specificity, good system durability, etc.
Claims
1. A method for detecting R-configuration and S-configuration enantiomers in a viloxazine drug, the method comprising: The method adopts a high performance liquid chromatography method, uses a silica gel covalently bonded with amylose-tris(3-chloro-5-methylphenylcarbamate) on the surface as a chromatographic column filler, and adopts an ultraviolet detector; the mobile phase A is an aqueous solution of ammonium bicarbonate, and the mobile phase B is acetonitrile, methanol, ethanol, isopropanol or a mixture thereof; the mobile phase A and the mobile phase B are used for elution; and the R-configuration and S-configuration enantiomers in the viloxazine drug are separated and detected; The structures of the R-configuration and S-configuration enantiomers in the viloxazine drug are as follows:
2. The method according to claim 1, characterized in that: The mobile phase A is an aqueous solution of 15-30 mM ammonium bicarbonate, preferably an aqueous solution of 20 mM ammonium bicarbonate.
3. The method according to claim 1, characterized in that: The mobile phase B is acetonitrile.
4. The method according to claim 1, characterized in that: The elution method is isocratic elution, wherein the volume ratio of mobile phase A to mobile phase B is (50-70):(30-50), preferably 65:
35.
5. The method according to claim 1, characterized in that: The elution method is linear gradient elution, and the elution conditions are:
6. The method according to claim 1, characterized in that: The chromatographic column used was CHIRALPAK IG, 4.6×250 mm, and the filler particle size was 5 μm.
7. The method according to any one of claims 1 to 6, characterized in that: The chromatographic conditions of the high performance liquid chromatography also include: The flow rate is 0.5-1.0 ml / min, preferably 0.6 ml / min; and / or, The column temperature is 20-40°C; and / or, The detection wavelength is 190nm to 230nm; and / or, The injection volume is 1 μl to 10 μl, preferably 5 μl.
8. The method according to any one of claims 1 to 6, characterized in that: Also included is the preparation of a test solution, comprising the following steps: taking the viloxazine drug substance or its drug preparation, accurately weighing it, and preparing it with a diluent; Optionally, the method further comprises the preparation of a reference solution, comprising the following steps: the reference solution is R-configuration and S-configuration enantiomers of viloxazine, the reference solution is accurately weighed, and the solution is prepared with a diluent respectively; The diluent is a mixed solution of mobile phases A and B, acetonitrile, methanol, or one or more of water.
9. The method according to claim 8, characterized in that: The concentration of the test solution is 0.3 mg / ml to 2 mg / ml, preferably 0.4 mg / ml; The concentration of the reference solution is 0.3 mg / ml to 2 mg / ml, preferably 0.4 mg / ml.
10. The method according to any one of claims 1 to 6, characterized in that: Also includes: Accurately measure the test solution and inject it into the liquid chromatograph, and record the chromatogram.
11. The method according to any one of claims 1 to 10, characterized in that: The viloxazine drug is a viloxazine bulk drug or a viloxazine drug preparation.
